EP0654080A1 - HIV gp120 EPITOPÄHNLICHE PEPTIDE - Google Patents

HIV gp120 EPITOPÄHNLICHE PEPTIDE

Info

Publication number: EP0654080A1
Authority: EP; European Patent Office
Prior art keywords: molecule; peptide; hiv; sequence; modified
Prior art date: 1992-07-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP93916096A

Other languages

English (en)

French (fr)

Inventor

Peter Jonathan Gasking Butler

Graeme Norman Varey Hacking

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Medical Research Council

Original Assignee

Medical Research Council

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-16

Filing date

1993-07-16

Publication date

1995-05-24

1993-07-16 Application filed by Medical Research Council filed Critical Medical Research Council

1995-05-24 Publication of EP0654080A1 publication Critical patent/EP0654080A1/de

Status Withdrawn legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 103
230000003278 mimic effect Effects 0.000 title claims abstract description 7
102000004196 processed proteins & peptides Human genes 0.000 title description 6
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 27
208000030507 AIDS Diseases 0.000 claims abstract description 19
230000002163 immunogen Effects 0.000 claims abstract description 16
229960005486 vaccine Drugs 0.000 claims abstract description 16
238000011282 treatment Methods 0.000 claims abstract description 10
239000004474 valine Substances 0.000 claims abstract description 5
150000001413 amino acids Chemical group 0.000 claims description 43
235000001014 amino acid Nutrition 0.000 claims description 39
238000000034 method Methods 0.000 claims description 13
239000002671 adjuvant Substances 0.000 claims description 10
238000011321 prophylaxis Methods 0.000 claims description 6
239000000969 carrier Substances 0.000 claims description 5
239000000427 antigen Substances 0.000 claims description 4
108091007433 antigens Proteins 0.000 claims description 4
102000036639 antigens Human genes 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
108020004414 DNA Proteins 0.000 claims description 3
102000053602 DNA Human genes 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical class C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 3
235000020776 essential amino acid Nutrition 0.000 claims description 3
239000003797 essential amino acid Substances 0.000 claims description 3
239000013604 expression vector Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 79
208000031886 HIV Infections Diseases 0.000 abstract description 33
241000713340 Human immunodeficiency virus 2 Species 0.000 abstract description 33
241000725303 Human immunodeficiency virus Species 0.000 abstract description 28
230000028993 immune response Effects 0.000 abstract description 8
238000001212 derivatisation Methods 0.000 abstract description 3
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 46
210000002966 serum Anatomy 0.000 description 37
241000283973 Oryctolagus cuniculus Species 0.000 description 29
229940024606 amino acid Drugs 0.000 description 29
108091036078 conserved sequence Proteins 0.000 description 22
241000700605 Viruses Species 0.000 description 18
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
230000000692 anti-sense effect Effects 0.000 description 10
239000012634 fragment Substances 0.000 description 10
239000002253 acid Substances 0.000 description 9
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 9
238000002649 immunization Methods 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
102100034349 Integrase Human genes 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
238000002965 ELISA Methods 0.000 description 6
235000018417 cysteine Nutrition 0.000 description 6
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
210000004201 immune sera Anatomy 0.000 description 5
229940042743 immune sera Drugs 0.000 description 5
238000010166 immunofluorescence Methods 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
150000007513 acids Chemical class 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000004132 cross linking Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
230000004044 response Effects 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
101710121417 Envelope glycoprotein Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000013461 design Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
241000894007 species Species 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
DXQOQMCLWWADMU-ACZMJKKPSA-N Asp-Gln-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O DXQOQMCLWWADMU-ACZMJKKPSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
YQEHNIKPAOPBNH-DCAQKATOSA-N Cys-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N YQEHNIKPAOPBNH-DCAQKATOSA-N 0.000 description 2
101710091045 Envelope protein Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 2
KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
241000282537 Mandrillus sphinx Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
101710188315 Protein X Proteins 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 2
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
235000005772 leucine Nutrition 0.000 description 2
108010090333 leucyl-lysyl-proline Proteins 0.000 description 2
239000000463 material Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
108010091748 peptide A Proteins 0.000 description 2
239000000047 product Substances 0.000 description 2
108010090894 prolylleucine Proteins 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
229940070741 purified protein derivative of tuberculin Drugs 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000035899 viability Effects 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
MFGALGYVFGDXIX-UHFFFAOYSA-N 2,3-Dimethylmaleic anhydride Chemical compound CC1=C(C)C(=O)OC1=O MFGALGYVFGDXIX-UHFFFAOYSA-N 0.000 description 1
KKYFGXDILCPMIT-UHFFFAOYSA-N 3-hydroxy-1,2-dihydro-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)NNC2=C1 KKYFGXDILCPMIT-UHFFFAOYSA-N 0.000 description 1
HWJNMTWBPYQWKU-UHFFFAOYSA-N 3-hydroxy-2-phenoxypropanoic acid Chemical compound OCC(C(O)=O)OC1=CC=CC=C1 HWJNMTWBPYQWKU-UHFFFAOYSA-N 0.000 description 1
VIGKUFXFTPWYER-BIIVOSGPSA-N Ala-Cys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N VIGKUFXFTPWYER-BIIVOSGPSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
HLTLEIXYIJDFOY-ZLUOBGJFSA-N Asn-Cys-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O HLTLEIXYIJDFOY-ZLUOBGJFSA-N 0.000 description 1
YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
102100025232 Calcium/calmodulin-dependent protein kinase type II subunit beta Human genes 0.000 description 1
QDFBJJABJKOLTD-FXQIFTODSA-N Cys-Asn-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QDFBJJABJKOLTD-FXQIFTODSA-N 0.000 description 1
NQSUTVRXXBGVDQ-LKXGYXEUSA-N Cys-Asn-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NQSUTVRXXBGVDQ-LKXGYXEUSA-N 0.000 description 1
HMWBPUDETPKSSS-DCAQKATOSA-N Cys-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CCCCN)C(=O)O HMWBPUDETPKSSS-DCAQKATOSA-N 0.000 description 1
OELDIVRKHTYFNG-WDSKDSINSA-N Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CS OELDIVRKHTYFNG-WDSKDSINSA-N 0.000 description 1
FNXOZWPPOJRBRE-XGEHTFHBSA-N Cys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)N)O FNXOZWPPOJRBRE-XGEHTFHBSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical group OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
101001077352 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit beta Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
WVUDHMBJNBWZBU-XUXIUFHCSA-N Ile-Lys-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)O)N WVUDHMBJNBWZBU-XUXIUFHCSA-N 0.000 description 1
NAFIFZNBSPWYOO-RWRJDSDZSA-N Ile-Thr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NAFIFZNBSPWYOO-RWRJDSDZSA-N 0.000 description 1
108010065920 Insulin Lispro Proteins 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 1
AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
JCVOHUKUYSYBAD-DCAQKATOSA-N Lys-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CS)C(=O)O JCVOHUKUYSYBAD-DCAQKATOSA-N 0.000 description 1
GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
241000220317 Rosa Species 0.000 description 1
WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
OYTNZCBFDXGQGE-XQXXSGGOSA-N Thr-Gln-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O OYTNZCBFDXGQGE-XQXXSGGOSA-N 0.000 description 1
IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
-1 acetamidomethyl Chemical group 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
108010060199 cysteinylproline Proteins 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000002434 immunopotentiative effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
150000002614 leucines Chemical class 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
108010017391 lysylvaline Proteins 0.000 description 1
230000035800 maturation Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Substances CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 1
QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

a live vaccine e.g. as part of the coat of a genetically modified virus such as polio or vaccinia.
a further aspect of the invention thus provides a method for the prophylaxis or treatment of AIDS or related conditions, comprising administering an effective amount of a molecule in accordance with the invention.
the invention provides a
the peptide was analysed by HPLC after synthesis and found to be at least 98% pure and was therefore used, without further purification, for coupling to KLH for immunisation of rabbits.
Figure 4 shows binding of sera from one rabbit (Pong) to cells infected with HIV-2.
the cells were either

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pressure Welding/Diffusion-Bonding (AREA)

EP93916096A 1992-07-16 1993-07-16 HIV gp120 EPITOPÄHNLICHE PEPTIDE Withdrawn EP0654080A1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9215129		1992-07-16
GB929215129A GB9215129D0 (en)	1992-07-16	1992-07-16	Development relating to human immunodeficiency viruses
PCT/GB1993/001503 WO1994002614A1 (en)	1992-07-16	1993-07-16	PEPTIDES THAT MIMIC gp120 HIV EPITOPE

Publications (1)

Publication Number	Publication Date
EP0654080A1 true EP0654080A1 (de)	1995-05-24

Family

ID=10718806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP93916096A Withdrawn EP0654080A1 (de)	1992-07-16	1993-07-16	HIV gp120 EPITOPÄHNLICHE PEPTIDE

Country Status (7)

Country	Link
EP (1)	EP0654080A1 (de)
JP (1)	JPH07509237A (de)
AU (1)	AU681591B2 (de)
CA (1)	CA2140151A1 (de)
GB (1)	GB9215129D0 (de)
WO (1)	WO1994002614A1 (de)
ZA (1)	ZA935165B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4402756A1 (de) *	1994-01-31	1995-08-03	Boehringer Mannheim Gmbh	Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine
US6911527B1 (en)	1999-01-11	2005-06-28	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	HIV related peptides
EP1159297A2 (de) *	1999-01-11	2001-12-05	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Hiv-verwandte peptide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8714802D0 (en) *	1987-06-24	1987-07-29	Proteus Biotech Ltd	Synthetic polypeptides
FR2617944B1 (fr) *	1987-07-06	1990-09-28	Macc Sa	Perfectionnement aux chevalets
GB8828097D0 (en) *	1988-12-01	1989-01-05	Wellcome Found	Peptides
CA2035576A1 (en) *	1990-02-07	1991-08-08	Alexander R. Neurath	Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 hiv-1

1992
- 1992-07-16 GB GB929215129A patent/GB9215129D0/en active Pending
1993
- 1993-07-16 JP JP6504265A patent/JPH07509237A/ja active Pending
- 1993-07-16 ZA ZA935165A patent/ZA935165B/xx unknown
- 1993-07-16 CA CA002140151A patent/CA2140151A1/en not_active Abandoned
- 1993-07-16 AU AU45788/93A patent/AU681591B2/en not_active Ceased
- 1993-07-16 WO PCT/GB1993/001503 patent/WO1994002614A1/en not_active Ceased
- 1993-07-16 EP EP93916096A patent/EP0654080A1/de not_active Withdrawn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9402614A1 *

Also Published As

Publication number	Publication date
WO1994002614A1 (en)	1994-02-03
CA2140151A1 (en)	1994-02-03
ZA935165B (en)	1994-03-14
JPH07509237A (ja)	1995-10-12
AU4578893A (en)	1994-02-14
GB9215129D0 (en)	1992-08-26
AU681591B2 (en)	1997-09-04

Legal Events

Date	Code	Title	Description
1995-04-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1995-05-24	17P	Request for examination filed	Effective date: 19941231
1995-05-24	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
1998-04-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
1998-05-20	18W	Application withdrawn	Withdrawal date: 19980401

Publication	Publication Date	Title
US5795955A (en)	1998-08-18	Tandem synthetic HIV-1 peptides
US5013548A (en)	1991-05-07	Production of antibodies to HIV
Rusche et al.	1988	Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
US5019387A (en)	1991-05-28	Production of antibodies to HIV
Palker et al.	1989	Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
US5589175A (en)	1996-12-31	Peptides for induction of neutralizing antibodies against human immunodeficiency virus
Conley et al.	1994	Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens
EP0762895B1 (de)	2002-08-07	Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
IE871289L (en)	1987-11-19	Peptides, antibodies, vaccines and assay methods.
US5688914A (en)	1997-11-18	Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus
US6080846A (en)	2000-06-27	Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus
WO1993005812A1 (en)	1993-04-01	Method to induce cytotoxic t lymphocytes specific for a broad array of hiv-1 isolates using hybrid synthetic peptides
AU681591B2 (en)	1997-09-04	Peptides that mimic gp120 HIV epitope
AU666160B2 (en)	1996-02-01	Compositions for eliciting cytotoxic T-lymphocyte responses against viruses
WO1989003813A1 (en)	1989-05-05	Anti-retroviral agent
AU6515394A (en)	1994-11-08	Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0498905A1 (de)	1992-08-19	Konformationsepitope des humanen Immundefizienzvirus-Hüllprotein-gp120
JP3725899B6 (ja)	2006-02-22	Ｈｉｖに対して使用するための多分岐ペプチド構築物
JP3725899B2 (ja)	2005-12-14	Ｈｉｖに対して使用するための多分岐ペプチド構築物
Zaghouani et al.	1991	Immunogenicity of Synthetic Peptides Corresponding to Various Epitopes of the Human Immunodeficiency Virus Envelope Protein
CA2085084A1 (en)	1993-06-19	Synthetic peptides comprising a cyclic hiv principal neutralizing determinant and a t-cell stimulatory epitope